Presentation is loading. Please wait.

Presentation is loading. Please wait.

Oral peanut immunotherapy in children with peanut anaphylaxis

Published byΛάχεσις Γκόφας Modified over 5 years ago

Similar presentations

Presentation on theme: "Oral peanut immunotherapy in children with peanut anaphylaxis"— Presentation transcript:

1 Oral peanut immunotherapy in children with peanut anaphylaxis
Katharina Blumchen, MD, Helen Ulbricht, Ute Staden, MD, Kerstin Dobberstein, John Beschorner, Lucila Camargo Lopes de Oliveira, MD, Wayne G. Shreffler, MD, PhD, Hugh A. Sampson, MD, Bodo Niggemann, MD, Ulrich Wahn, MD, Kirsten Beyer, MD  Journal of Allergy and Clinical Immunology  Volume 126, Issue 1, Pages e1 (July 2010) DOI: /j.jaci Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study protocol. Black arrow, Visit (patient history/physical examination/blood drawing/SPT). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Flow diagram of children with peanut allergy recruited into the study. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Correlation of peanut-specific IgE and the tolerated peanut dose after OIT following the rush protocol. Shown is the inverse correlation between level of peanut specific IgE (kUA/L) at enrollment vs tolerated dose of peanut after 7 days of OIT after the rush protocol (P = .003; Spearman r = –0.6). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Clinical responses after OIT following the long-term buildup protocol. Shown are the tolerated peanut doses at baseline DBPCFC and at final DBPCFC post-OIT following the long-term buildup protocol of 14 patients who completed the whole study. The horizontal line represents the median of tolerated peanut dose. ∗∗P < .01. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Comparison of laboratory and SPT results pre-OIT at baseline DBPCFC, directly post-OIT, and 2 weeks off OIT before final DBPCFC. Shown are IL-5 (A), IL-4 (B), IL-2 (C), wheal size diameter (D), peanut-specific IgE (E), and IgG4(F) for 14 patients who completed the study (∗P < .05; ∗∗P < .01; ∗∗∗P < .001). Selected patients are marked (#) to follow the individual course. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Oral peanut immunotherapy in children with peanut anaphylaxis"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.

Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.
The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy  Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy  Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Omalizumab facilitates rapid oral desensitization for peanut allergy

Omalizumab facilitates rapid oral desensitization for peanut allergy
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M

Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Is the prevalence of peanut allergy increasing

Is the prevalence of peanut allergy increasing
Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B
Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy  Kamal D. Srivastava, PhD, Alyssa Siefert,

Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy  Kamal D. Srivastava, PhD, Alyssa Siefert,
Omalizumab facilitates rapid oral desensitization for peanut allergy

Omalizumab facilitates rapid oral desensitization for peanut allergy

Similar presentations

Ads by Google